- Home
- MIRM vs DNP Comparison
MIRM vs DNP Comparison
Compare MIRM & DNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- DNP
- Stock Information
- Founded
- MIRM 2018
- DNP 1986
- Country
- MIRM United States
- DNP United States
- Employees
- MIRM N/A
- DNP N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- DNP Investment Managers
- Sector
- MIRM Health Care
- DNP Finance
- Exchange
- MIRM Nasdaq
- DNP Nasdaq
- Market Cap
- MIRM 3.7B
- DNP 3.8B
- IPO Year
- MIRM 2019
- DNP N/A
- Fundamental
- Price
- MIRM $70.45
- DNP $10.13
- Analyst Decision
- MIRM Strong Buy
- DNP
- Analyst Count
- MIRM 11
- DNP 0
- Target Price
- MIRM $82.82
- DNP N/A
- AVG Volume (30 Days)
- MIRM 596.2K
- DNP 479.6K
- Earning Date
- MIRM 11-04-2025
- DNP 01-01-0001
- Dividend Yield
- MIRM N/A
- DNP 7.88%
- EPS Growth
- MIRM N/A
- DNP N/A
- EPS
- MIRM N/A
- DNP 2.30
- Revenue
- MIRM $471,794,000.00
- DNP $154,887,179.00
- Revenue This Year
- MIRM $53.14
- DNP N/A
- Revenue Next Year
- MIRM $19.83
- DNP N/A
- P/E Ratio
- MIRM N/A
- DNP $4.26
- Revenue Growth
- MIRM 53.66
- DNP 3.30
- 52 Week Low
- MIRM $36.88
- DNP $8.69
- 52 Week High
- MIRM $78.55
- DNP $10.04
- Technical
- Relative Strength Index (RSI)
- MIRM 50.06
- DNP 52.96
- Support Level
- MIRM $68.60
- DNP $10.01
- Resistance Level
- MIRM $73.02
- DNP $10.22
- Average True Range (ATR)
- MIRM 3.10
- DNP 0.10
- MACD
- MIRM 0.08
- DNP -0.01
- Stochastic Oscillator
- MIRM 54.27
- DNP 67.92
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About DNP DNP Select Income Fund Inc.
DNP Select Income Fund Inc is a closed-ended investment management fund. The primary investment objectives of the fund are current income and long-term growth of income. Its secondary objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing in the public utility industry.